Asset Details
Do you wish to reserve the book?
Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential
Do you wish to request the book?
Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential
2014
Overview
Objectives
We studied whether plasma levels of angiogenic factors VEGF and placental growth factor (PlGF) in coronary artery disease patients or undergoing cardiac surgery are modified, and whether those factors modulate endothelial progenitor’s angiogenic potential.
Methods and results
A total of 143 patients’ plasmas from two different studies were analyzed (30 coronary artery disease patients, 30 patients with stable angina, coupled with 30 age and sex-matched controls; 53 patients underwent cardiac surgery). Among factors screened, only PlGF was found significantly increased in these pathological populations. PlGF-1 and PlGF-2 were then tested on human endothelial-colony-forming cells (ECFCs). We found that PlGF-1 and PlGF-2 induce VEGFR1 phosphorylation and potentiate ECFCs tubulogenesis in vitro. ECFCs VEGFR1 was further inhibited using a specific small interfering RNA (siRNA) and the chemical compound
4321
. We then observed that the VEGFR1-siRNA and the compound
4321
decrease ECFCs tubulogenesis potential in vitro. Finally, we tested the compound
4321
in the preclinical Matrigel
®
-plug model with C57Bl/6J mice as well as in the murine hindlimb ischemia model. We found that
4321
inhibited the plug vascularization, attested by the hemoglobin content and the VE-Cadherin expression level and that
4321
inhibited the post-ischemic revascularization.
Conclusion
PlGF plasma levels were found increased in cardiovascular patients. Disrupting PlGF/VEGFR1 pathway could modulate ECFC-induced tubulogenesis, the cell type responsible for newly formed vessels in vivo.
Publisher
Springer Netherlands,Springer Nature B.V,Springer Verlag
Subject
/ Biomedical and Life Sciences
/ Cell Differentiation - drug effects
/ Cell Proliferation - drug effects
/ Coronary Artery Disease - blood
/ Coronary Artery Disease - pathology
/ Endothelial Cells - drug effects
/ Endothelial Cells - metabolism
/ Humans
/ Neovascularization, Physiologic - drug effects
/ Oncology
/ Phosphorylation - drug effects
/ Recombinant Proteins - pharmacology
/ RNA, Small Interfering - metabolism
/ Vascular Endothelial Growth Factor A - blood
/ Vascular Endothelial Growth Factor Receptor-1 - metabolism
